Open-Label, Randomized, Parallel, Comparative Clinical Study of Antihypertensive Efficacy of Generic and Brand Fixed-Dose Combinations Irbesartan and Hydrochlorothiazide in Hypertension II–III Degree

Yu.M. Sirenko, H.D. Radchenko, S.A. Polishchuk, P.I. Sidorenko

Abstract


-

References


Артеріальна гіпертензія — медико-соціальна проблема / В.М. Коваленко, М.І. Лутай, Є.П. Свіщенко, Ю.М. Сіренко, І.П. Смірнова. — К.: Інститут кардіо­логії ім. М.Д. Стражеска АМН України, 2002. — 102 с.

Горбась І.М. Контроль артеріальної гіпертензії серед населення: стан проблеми за даними епідеміологічних досліджень // Укр. кардіол. журнал. — 2007. — № 2. — С. 21-26.

Настанова та клінічний протокол надання медичної допомоги «Артеріальна гіпертензія». Наказ МОЗ України № 384 від 24.05.2012. — Київ, 2012. — 107 с.

Рекомендації Українського товариства кардіологів з профілактики та лікування артеріальної гіпертензії. — Київ: Віпол, 2008. — 83 с.

2007 European Society of Hypertension — European Society of Cardio­logy guidelines for management of arterial ­hypertension // J. Hypertension. — 2007. — Vol. 25. — P. 1105-1187.

2013 ESH/ESC Guidelines for the management of arterial hypertension TheTask Force for the management ofarterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) // Journal of Hypertension. — 2013. — Vol. 31. — P. 1281-1357.

Arhofer K.G., Muenzel F., Krekler M. Effect of the Angiotensin Receptor Blocker Irbesartan on Metabolic Parameters in Clinical Practice: the DO­IT Prospective Observational Study // Cardiovasc. Diabetol. — 2007. — 6(1). — P. 36.

Basta E., Barkis.G. Сhoices and goals in the treatment of diabetic hypertensive patients // Curr. Hypert. Rep. — 2001. — Vol. 3. — P. 387-391.

Bonds D., Palla S., Bertoni A. et al. Hypertension Treatment in the Ambulatory Setting: comparison by race and gender in a National survey // J. Clin. Hypertens. — 2004. — Vol. 6. — P. 223-230.

Bramlage P., Durand-Zaleski I., Desai N., Pirk O., Ha-cker C. The value of irbesartan in the management of hypertension // Expert Opin. Pharmacother. — 2009. — Vol. 10. — P. 1817-31.

Burt V.L., Cutler J.A., Higgins M. et al. Тrends in the prevalence, awareness, treatment and control of hypertension in the adult US population. Data from the health examination surveys 1960–1991 // Hypertens. — 1995. — Vol. 26. — P. 60-65.

Chatellier G., Menard J., Devries C. et al. Blood pressure control in hyper­tension center // J. Hypertens. — 1987. — Vol. 5. — P. 47-49S.

Elliot H., Connel J., McInnes G. The Year in hypertension. — Clinical Publishing Services Ltd: Oxford, 2001. — 369 p.

Fogari R., Ambrosoli S., Corradi L. et al. 24-hour blood pressure control by once-daily administration of irbesartan assessed by ambulatory blood pressure monitoring: Irbesartan Multicenter Investigators’ Group // J. Hypertens. — 1997. — Vol. 15. — P. 1511-1518.

Havranek E.P., Thomas I., Smith W.B. et al. Dose-related be-neficial long­term hemodynamic and clinical efficacy of irbesartan in heart failure // J. Am. Coll. Cardiol. — 1999. — Vol. 33. — P. 1174-1181.

Hypertension Primer. The essentials of high blood pressure. Basic science. Population science and clinical management. Fourth edition. From the council on high blood pressure research American Heart Association. — Lippincott Williams & Wilkins: Dallas, 2008. — 610 p.

Kintscher U., Bramlage P., Paar W.D. et al. Irbesartan for the treatment of hypertension in patients with the metabolic syndrome: a sub analysis of the Treat to Target post authorization survey. Prospective observational, two armed study in 14,200 patients // Cardiovasc. Diabetol. — 2007. — 6. — P. 12.

Lewis E.J., Hunsicker L.G., Clarke W.R. et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes // N. Engl. J. Med. — 2001. — 345. — P. 851-860.

Mancia G., Sega R., Milesi C. et al. Blood pressure control in the hypertensive population // Lancet. — 1997. — Vol. 348. — P. 454-457.

Massie B.M., Carson P.E., McMurray J.J. et al. Irbesartan in patients with heart failure and preserved ejection fraction // N. Engl. J. Med. — 2008. — Vol. 359. — P. 172.

Moser M. Clinical management of Hypertension. Fourth Edition. — Caddo: Professional Communications, Inc., 1999. — 240 p.

Parving H.H., Lehnert H., Brochner-Mortensen J. et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes // N. Engl. J. Med. — 2001. — 345. — P. 870-8.

The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. US Department of Health and Human Service. NIH Publication No. 03-5233, 2003. — 34 p.

Urata H., Healey B., Stewart R.W., Bumpus F.M., Husain A., Angiotensin II-Forming Pathways in Normal and Failing Human Hearts // Cirs. Res. ­1990. — Vol. 66. — P. 883-90.

White W. Blood pressure monitoring in Cardiovascular Medi­cine and Therapeutics. — N. Jersy: Humana Press, 2001. — 308 p.




DOI: https://doi.org/10.22141/2224-1485.2.40.2015.80639

Copyright (c) 2016 HYPERTENSION

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

 

© Publishing House Zaslavsky, 1997-2018

 

   Seo анализ сайта